SecBot SecBot
25-NSE ·Filed Sep 3, 2026

APGE

Apogee Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonimmediate Processed2mo ago SEC0001354457-26-000853
Notable filing: 25-NSE
Actionable Insight ▲ Bullish

The merger is complete and the stock will be delisted. Traders holding APGE shares should have already tendered them for the $135.11 cash consideration. There is no further trading opportunity in APGE; any remaining positions should be settled through the merger consideration process.

DirectionBullish
Confidencehigh
Horizonimmediate

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Apogee Therapeutics has been acquired by AbbVie in a completed all-cash merger valued at approximately $10.9 billion. Shareholders received $135.11 per share in cash, and the company's stock will be delisted from Nasdaq effective September 4, 2026. This 25-NSE filing is the formal notification by Nasdaq of the removal from listing and registration of Apogee's common stock, confirming the completion of the merger and the end of public trading in APGE shares.

Key Facts

  • Apogee Therapeutics has been acquired by AbbVie in a completed all-cash merger valued at approximately $10.9 billion.
  • Shareholders received $135.11 per share in cash.
  • The company's stock will be delisted from Nasdaq effective September 4, 2026.
  • This 25-NSE filing is the formal notification by Nasdaq of the removal from listing and registration of Apogee's common stock.
  • The filing confirms the consummation of the previously announced merger, resulting in a change of control and the termination of all pre-merger equity plans.

Financial Impact

All-cash merger valued at approximately $10.9 billion, with shareholders receiving $135.11 per share.

revenueepsdebtdilution

Risk Factors

  • No further trading opportunity in APGE shares; delisting is effective immediately.
  • Any remaining shareholders who have not tendered shares may face delays or additional steps to receive the merger consideration.
  • The merger consideration is fixed at $135.11 per share; there is no upside beyond this amount.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
29% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
25-NSE Filing (Primary)0001354457-26-000853
Document: 0001354457-26-000853-index-headers.html0001354457-26-000853
Document: 0001354457-26-000853-index.html0001354457-26-000853
Document: 0001354457-26-000853.txt0001354457-26-000853

Track record

31 reports on APGE

Performance horizon

9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.

Filters
  1. Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
  2. Sep 3, 202610w ago 25-NSE Bullish 8/10 Viewing Entry $135.06 No price data
  3. Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
  4. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
  5. Aug 10, 202614w ago 8-K Bullish 8/10 No price data
  6. Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
  7. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
  8. Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
  9. Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
  10. Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens in 8h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 3, 2026